Realize the Potential of Rapid-Acting Treatments for Depression
Earn up to 1.0 pharmacology CE hour
Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP | Click here for information about Josh Hamilton
Traditional monoaminergic antidepressants remain the standard of care, yet their limitations—low response rates, suboptimal efficacy, and challenging side effects—leave many patients struggling. It's time to think beyond serotonin. Join Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP, for a deep dive into the evolving science of depression treatment, including the role of glutamatergic and GABAergic modulation.
Explore groundbreaking pharmacologic advancements, from neuroactive steroids to glutamatergic antidepressants, and discover when these emerging therapies are the right choice. Through real-world case applications, gain prescriptive insights that will transform the way you approach depression management.
Earn up to 1.0 pharmacology CE hour
Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP | Click here for information about Josh Hamilton
Traditional monoaminergic antidepressants remain the standard of care, yet their limitations—low response rates, suboptimal efficacy, and challenging side effects—leave many patients struggling. It's time to think beyond serotonin. Join Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP, for a deep dive into the evolving science of depression treatment, including the role of glutamatergic and GABAergic modulation.
Explore groundbreaking pharmacologic advancements, from neuroactive steroids to glutamatergic antidepressants, and discover when these emerging therapies are the right choice. Through real-world case applications, gain prescriptive insights that will transform the way you approach depression management.